| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oleocanthal is essentially found ONLY in: Fresh, unrefined extra-virgin olive oil (EVOO) It is part of the pungent, throat-stinging phenolic fraction that disappears in refined oils. Oleuropein (OLEU) — a secoiridoid polyphenol from olive leaf and olive fruit/extra-virgin olive oil; major in-vivo related phenolic is hydroxytyrosol (via hydrolysis/metabolism). Sources: olive leaf extract (standardized to oleuropein), EVOO phenolics. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Human data show absorption/metabolism after oral olive leaf extract; circulating forms are largely metabolites (and hydroxytyrosol-related), with limited free parent compound exposure. :contentReference[oaicite:0]{index=0} In-vitro vs oral exposure: Many direct “anticancer” cytotoxic effects occur at micromolar concentrations that may exceed typical systemic exposure from supplements/foods (high concentration only for direct tumor cytotoxicity in many models). :contentReference[oaicite:1]{index=1} Clinical evidence status: Nutraceutical/food bioactive with human data mainly for cardiometabolic/inflammation endpoints; oncology evidence largely preclinical/adjunct-hypothesis (no oncology approval). Also available as a supplement usually labeled as Olive Leaf Extract. (20-50% concentrations)- commonly used in CSC (Cancer Stem Cell) research. Main CSC mechanisms: -Inhibits Wnt/β-catenin — a core CSC survival pathway -↓ALDH (Reduces ALDH-high CSC subpopulations) -downregulates stemness geens: SOX2/OCT4/Nanog → reduced sphere formation/self-renewal. Oleuropein — Cancer vs Normal Cell Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr Oleuropein — AD relevance: Oleuropein/olive leaf phenolics show neuroprotection in models via oxidative- and heat-shock/proteostasis stress responses, with reported reduction of Aβ and tau proteotoxicity in preclinical systems; human AD disease-modifying evidence is not established. Primary mechanisms (conceptual rank): Bioavailability / PK relevance: Human absorption/metabolism supports systemic exposure mainly as metabolites; brain relevance likely chronic/adaptive. :contentReference[oaicite:9]{index=9} Clinical evidence status: Predominantly preclinical for AD mechanisms; limited AD-specific clinical endpoint evidence. Oleuropein — AD / Neurodegeneration Pathway Map
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| Vimentin, a major constituent of the intermediate filament family of proteins, is ubiquitously expressed in normal mesenchymal cells and is known to maintain cellular integrity and provide resistance against stress. Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure. In many epithelial-derived tumors (carcinomas), elevated Vimentin expression is often observed in cancer cells that have undergone EMT. This upregulation is characteristic of a shift toward a mesenchymal state, which is associated with reduced cell–cell adhesion and increased motility. Vimentin expression is also noted in the tumor stroma, reflecting the presence and activation of mesenchymal cells such as cancer-associated fibroblasts (CAFs). This dual expression can contribute to the remodeling of the tumor microenvironment. The degree of Vimentin expression may vary depending on the tumor type, grade, and stage. More aggressive and advanced tumors tend to show higher levels of Vimentin expression. High Vimentin expression has been correlated with poor clinical outcomes in several cancers, including breast, colorectal, prostate, and lung cancers. Elevated Vimentin levels are typically associated with higher tumor grade, increased invasiveness, enhanced metastatic potential, and a greater risk of recurrence. As a component of the EMT signature, high Vimentin expression can serve as an indicator of a more aggressive tumor phenotype and is often associated with reduced overall survival. - vimentin up-regulation is often used as a marker of EMT in cancer |
| 4630- | OLE, | Targeting resistant breast cancer stem cells in a three-dimensional culture model with oleuropein encapsulated in methacrylated alginate microparticles |
| - | in-vitro, | BC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:375 Target#:336 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid